Latest Hansa Biopharma News & Updates

See the latest news and media coverage for Hansa Biopharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

Hansa Biopharma

Developer of immunomodulatory treatments for rare immunological diseases

hansabiopharma.com

Headquarters: Lund, Sweden
Founded year: 2007
Company type: Public company
Number of employees: 125–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Hansa Biopharma

In short: Hansa Biopharma strengthened its financial position through a €115M licensing deal with SERB and secured a December 2026 FDA PDUFA date.

Company announcements

July 22 Hansa Biopharma

Hansa Biopharma reports Q2 and H1 2026 financial results

Highlights include €115m out-licensing deal and positive PAES data supporting full European approval.

July 8 Hansa Biopharma

Hansa Biopharma announces Q2 2026 interim results conference call

The report covers January-June 2026, and management will review results and provide business and pipeline update.

July 1 Hansa Biopharma

Hansa Biopharma closes €115M licensing transaction with SERB

The deal grants SERB exclusive rights to commercialize Idefirix in Europe and MENA, strengthening Hansa's finances for US launch.

June 15 Hansa Biopharma

Hansa Biopharma appoints Adam Cutler as CFO

He succeeds retiring Evan Ballantyne, effective June 22, 2026.

Media coverage

July 30 Affärsvärlden

Related party to Hansa Biopharma board member sells for 17,7 million

Devin Holden, related party to the biotech company Hansa Biopharma's board member Michael Bologna has sold 467 166 shares.

July 24 Affärsvärlden

Major report movements on the Stockholm Stock Exchange

The Stockholm Stock Exchange rises at lunchtime on Friday.

July 24 Affärsvärlden

SEB raises target price sharply – stock surges 30%

SEB reiterates buy on biotech company Hansa Biopharma and raises target price to SEK 150 from SEK 100.

July 23 Dagens industri

SEB sees upside of 388 percent: 'The most important factor'

SEB raises target price for Hansa Biopharma from 100 to 150 kronor. The new target price is 388 percent above yesterday's closing price. 'We believe that Hansa...'

Never miss news about Hansa Biopharma

Track Hansa Biopharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Hansa Biopharma competitors & trending companies

Browse news for competitors to Hansa Biopharma and other trending companies.